Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript
Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Cerevel with us. Just quickly before we get started, I need to make a disclosure statement.
Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures. With that, really happy to have Tony Coles, who is the CEO at Cerevel. Tony, I'm going to let you make some opening comments, and then we can jump into it.
Okay. Good. Well, good morning, Matthew. Thank you for having us. I will be making some forward-looking statements. So that's our disclaimer at the front. Cerevel is a company that was formed 4 years ago as a result of the spinout of the Pfizer Neuroscience assets, which anyone, who
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
